KPIs & Operating Metrics(New)
Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios
Asset Utilization RatioAssets AverageDebt RatioDebt to EquityEBIT MarginEBITDA MarginEBT MarginEnterprise ValueEquity AverageEquity RatioFCF MarginGross MarginInterest Coverage RatioInventory AverageInvested CapitalNet MarginOperating MarginReturn on AssetsReturn on Capital EmployedReturn on EquityReturn on Invested CapitalReturn on SalesTimes Interest Earned

Halozyme Therapeutics (HALO) EBT Margin (2016 - 2025)

Halozyme Therapeutics (HALO) has disclosed EBT Margin for 16 consecutive years, with 22.32% as the latest value for Q4 2025.

  • Quarterly EBT Margin fell 8212.0% to 22.32% in Q4 2025 from the year-ago period, while the trailing twelve-month figure was 33.43% through Dec 2025, down 2144.0% year-over-year, with the annual reading at 33.43% for FY2025, 2144.0% down from the prior year.
  • EBT Margin for Q4 2025 was 22.32% at Halozyme Therapeutics, down from 61.81% in the prior quarter.
  • The five-year high for EBT Margin was 67.07% in Q2 2021, with the low at 22.32% in Q4 2025.
  • Average EBT Margin over 5 years is 45.63%, with a median of 49.96% recorded in 2024.
  • The sharpest move saw EBT Margin soared 5558bps in 2021, then crashed -8212bps in 2025.
  • Over 5 years, EBT Margin stood at 53.73% in 2021, then decreased by -27bps to 39.0% in 2022, then grew by 13bps to 43.98% in 2023, then surged by 36bps to 59.8% in 2024, then tumbled by -137bps to 22.32% in 2025.
  • According to Business Quant data, EBT Margin over the past three periods came in at 22.32%, 61.81%, and 62.92% for Q4 2025, Q3 2025, and Q2 2025 respectively.